ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CTOR / forecast
CNTB (26) HRTX (34) XLO (25) PLRX (34) ⌘ Pro Terminal →

Citius Oncology Inc. (CTOR) 12-Month Stock Forecast & Price Target Cone

$0.59 +7.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.60

Citius Oncology Inc. (CTOR) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $51.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CTOR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CTOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Citius Oncology Inc. (NASDAQ: CTOR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.59 (+7.24% 1D, market cap $51.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CTOR ranks #643 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CTOR compare to CNTB and HRTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTOR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CNTB (Connect Biopharma Holdings Limited) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $50.5M) and HRTX (Heron Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $52.7M). Among the 5-stock peer group, CTOR leads on earnings multiple (N/A) while CTOR leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CTOR?
▼

Per CTOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001851484), Citius Oncology Inc. generated $65.9M in revenue (+14.3% YoY), -$24.8M in net income, and -$5.5M in free cash flow against $110.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.60 (+1.11%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (7)Whales (8)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-10.2% Base Target
$2 Bull$1 Base$0 Bear
📬 FREE CTOR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTOR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY CTOR SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$0.79-15.2% Next Q
Q2 (-2Q)
39
Grade E$0.67-9% Next Q
Q3 (-1Q)
37
Grade E$0.61-3.3% Next Q
Current
34
Grade E$0.59-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CTOR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CTOR currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.83) and Max Pain ($0.62) forces dealer call-delta covering toward $1.92.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTOR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CTOR Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CTOR Position Size: $10,000

Shares at $0.59: 16949.2 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.41
$6,949
$-3,051 (-30.5%)
12M Consensus BaseTarget $0.53
$8,983
$-1,017 (-10.2%)
12M Bull Case BreakoutTarget $1.92
$32,542
+$22,542 (+225.4%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$269%B
JP MorganUS Large-Cap ResearchSELL$058%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTOR)

  • ✓Walkthrough of CTOR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CTOR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.87%📐 HORIZONTAL RANGE
2026-11-03O $0.53H $0.59L $0.53C $0.59VOL 292.8K
RES: $1.34SUP: $0.49SMA50: $0.83SMA200: $0.83
$1.40$1.16$0.91$0.67$0.42RES $1.34SUP $0.49$0.592026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTOR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CTOR Butterfly Map → + Track CTOR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +14.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CTOR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CTOR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CTOR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTOR)

Health Care Rank #643 of 1015 ⚔️ CNTB vs CTOR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CTOR vs. CNTB, HRTX, XLO, PLRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Citius Oncology Inc. (CTOR) ranks #643 by composite RQD confidence (34/100, grade E) and #740 by equity capitalization ($51.5M). Within this direct 5-issuer industry benchmark cohort, CTOR leads on earnings valuation at N/A trailing P/E, while CTOR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CTOR currently leads its immediate peer cohort in composite quantitative strength at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CTOR ACTIVE
Citius Oncology Inc.
E 34/100 — — -35.0% +7.24% $51.5M Benchmark Subject
CNTB
Connect Biopharma Holdings Limited
E 26/100 — — -35.0% -3.13% $50.5M /cntb-vs-ctor →
HRTX
Heron Therapeutics Inc.
E 34/100 — 73.3% -35.0% +6.27% $52.7M /hrtx-vs-ctor →
XLO
Xilio Therapeutics Inc.
E 25/100 — — -35.0% -0.50% $52.8M /xlo-vs-ctor →
PLRX
Pliant Therapeutics Inc.
E 34/100 — — -35.0% -2.29% $53.2M /plrx-vs-ctor →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001851484 ↗

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Citius Oncology Inc. (CTOR) reported GAAP revenue of $65.9M (+14.3% vs. FY2024 revenue of $57.6M , and +2221.9% cumulative change since FY2023) , GAAP net income of -$24.8M, operating cash flow of -$5.5M, and free cash flow of -$5.5M (-4446.6% YoY). On the balance sheet, CTOR closed FY2025 with $110.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-09-30 $65.9M -$24.8M -$5.5M -$5.5M $110.0M —
FY2024 (FY) 2024-09-30 $57.6M -$21.1M $126.4K $126.4K $90.5M —
FY2023 (FY) 2023-12-31 $2.8M $2.4M -$601.3K -$601.3K — —

3. CTOR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Citius Oncology Inc. (NASDAQ: CTOR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.59 (+7.24% 1D, market cap $51.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CTOR ranks #643 in composite RQD confidence.

How does CTOR compare to CNTB and HRTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTOR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CNTB (Connect Biopharma Holdings Limited) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $50.5M) and HRTX (Heron Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $52.7M). Among the 5-stock peer group, CTOR leads on earnings multiple (N/A) while CTOR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CTOR?

Per CTOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001851484), Citius Oncology Inc. generated $65.9M in revenue (+14.3% YoY), -$24.8M in net income, and -$5.5M in free cash flow against $110.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CTOR trading relative to its 50-day, 200-day, and 52-week technical levels?

CTOR last traded at $0.59 (+7.24% on volume of 378,810 shares), positioning the stock -28.92% below its 50-day simple moving average ($0.83) and -28.92% below its 200-day simple moving average ($0.83). Across its 52-week range of $0.49 to $1.83, CTOR sits at the 7.5% percentile with a 14-day RSI of 31.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.66).

Direct Sub-Reports: CTOR RQD Cockpit CTOR 12M Forecast CTOR Earnings & Move CTOR Dividends & DRIP CTOR Insiders & 13F CTOR Whale Options CTOR Profit Sankey CTOR News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

CTOR — Citius Oncology Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-09-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Citius Oncology Inc. (CTOR) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.59 (+7.24% 1D, market capitalization $51.5M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -11.16%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Citius Oncology Inc. (CTOR) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is $0.0B, which conflicts with the $49.2M figure in the market data and should be treated cautiously. — describes its products, customers, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), Citius Oncology Inc. (CTOR) reported $65.9M in annual revenue (up from $57.6M in FY2024, +14.3% YoY) and -$24.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.8M revenue, $2.4M net income) through FY2025, CTOR scaled operating cash flow to -$5.5M and free cash flow to -$5.5M, backed by $110.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -11.16% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.49 – $1.83 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. An investor should watch for any future disclosures on manufacturing, licensing, or distribution partners, as the absence of mapped links means ripple effects from suppliers or customers are not assessable here.

  • Key Question #1: Can CTOR sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $65.9M and free cash flow of -$5.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CTOR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CTOR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Citius Oncology Inc. (CTOR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CTOR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CTOR Bull vs. Bear Conversation Board — What's Your Call at $0.59?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CTOR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CTOR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $0.69 (+25.5%)
📌 Pinned Debate

Institutional interest is visible, with 54 institutions having ordered LYMPHIR, up from 44 as of Aug. 14.

Long CTOR at $0.55 targeting $0.69. Institutional interest is visible, with 54 institutions having ordered LYMPHIR, up from 44 as of Aug. 14.. Institutional whale score is 8/20 and the risk/reward vs. the $0.49 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@BearTrap_Alert Shorting a 8/20 institutional whale-flow stock at $0.55 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $0.41 (-25.5%)
Spot @ $0.55

Negative ROIC of -35% and FCF yield of -11.16% show the business is consuming capital while trading below $1 under Nasdaq bid-price rev

I respect the product at Citius Oncology Inc., but the stock at $0.55 is a different story. Negative ROIC of -35% and FCF yield of -11.16% show the business is consuming capital while trading below $1 under Nasdaq bid-price review.. FCF yield is -11.16% and RQD sits at 34/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%